Premium
Chronic total occlusion: Does anti‐platelet choice impact outcomes?
Author(s) -
Shatila Wassim,
Krajcer Zvonimir
Publication year - 2018
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27456
Subject(s) - medicine , ticagrelor , conventional pci , percutaneous coronary intervention , clopidogrel , p2y12 , cardiology , vasomotor , coronary occlusion , occlusion , myocardial infarction
Key Points Chronic total occlusion (CTO) is associated with worse outcomes compared to non CTO percutaneous coronary intervention (PCI). CTO might be associated with vasomotor dysfunction Ticagrelor is a novel P2Y12 inhibitor that increases local adenosine The TIGER‐BVS trial plans to assess the impact of using ticagrelor vs. clopidogrel on vasomotor activity and outcomes after successful CTO PCI.